Genetic thrombophilia

Primary Care - Clinics in Office Practice

Volumn 31, Issue 3, 2004, Pages 685-709

  Feero, W Gregory ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Maine Dartmouth Family Practice Residency   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; CITALOPRAM; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S; PROTHROMBIN; WARFARIN;

AGING; ANTITHROMBIN DEFICIENCY; DEEP VEIN THROMBOSIS; FAMILY HISTORY; GENE MUTATION; GENETIC DISORDER; HETEROZYGOSITY; HOMEOSTASIS; HORMONE SUBSTITUTION; HUMAN; HYPERHOMOCYSTEINEMIA; PHYSICAL EXAMINATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; THROMBOPHILIA;

ADULT; AGED; CHILD; FACTOR V; FEMALE; HUMANS; MALE; PROTHROMBIN; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 4344571511     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2004.04.014     Document Type: Review

References (135)

1. Rosendaal F.R. Venous thrombosis: a multicausal disease. Lancet. 353:1999;1167-1173
2. Ridker P.M. Inherited risk factors for venous thromboembolism: implications for clinical practice. Clin Cornerstone. 4:2002;18-30
3. Bertina R.M., Rosendaal F.R. Venous thrombosis - the interaction of genes and environment. N Engl J Med. 338:1998;1840-1841
4. Bertina R.M., Koeleman B.P., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67
5. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 88:1996;3698-3703
6. Berne R.M., Levy M.N. Physiology. 2nd edition :1988;CV Mosby, St. Louis
7. Cotran R.S., Kumar V., Collins T. Robbins pathologic basis of disease. 6th edition :1999;WB Saunders, Philadelphia
8. Kottke-Marchant K. Genetic polymorphisms associated with venous and arterial thrombosis: an overview. Arch Pathol Lab Med. 126:2002;295-304
9. Virchow R. Phlogose und Thrombose im Gefasssystem. 1856.
10. Khoury M.J., Beaty T.H., Cohen B.H. Fundamentals of genetic epidemiology, vol. 19. 1993;Oxford University Press, New York
11. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost. 86:2001;395-403
12. Sykes T.C., Fegan C., Mosquera D. Thrombophilia, polymorphisms, and vascular disease. Mol Pathol. 53:2000;300-306
13. Key N.S., McGlennen R.C. Hyperhomocyst(e)inemia and thrombophilia. Arch Pathol Lab Med. 126:2002;1367-1375
14. Thrombophilia website. Available at: www.ncbi.nlm.nih.gov/Omim/ searchomim.html. Accessed November 17, 2003.
15. Seligsohn U., Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 344:2001;1222-1231
16. Miletich J.P. Thrombophilia as a multigenic disorder. Semin Thromb Hemost. 24:(Suppl 1):1998;13-20
17. Tsai A.W., Cushman M., Tsai M.Y., et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism. Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Hematol. 72:2003;192-200
18. Ray J.G., Shmorgun D., Chan W.S. Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol Haemost Thromb. 32:2002;51-58
19. Jennings I., Cooper P. Screening for thrombophilia: a laboratory perspective. Br J Biomed Sci. 60:2003;39-51
20. Perry S.L., Ortel T.L. Clinical and laboratory evaluation of thrombophilia. Clin Chest Med. 24:2003;153-170
21. Crowther M.A., Kelton J.G. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med. 138:2003;128-134
22. Bauer K.A., Rosendaal F.R., Heit J.A. Hypercoagulability: too many tests, too much conflicting data. Hematology (Am Soc Hematol Educ Program). 2002;353-368. 2002
23. Burke W. Genetic testing. N Engl J Med. 347:2002;1867-1875
24. Guttmacher A.E., Collins F.S. Genomic medicine - a primer. N Engl J Med. 347:2002;1512-1520
25. Nabel E.G. Cardiovascular disease. N Engl J Med. 349:2003;60-72
26. Nicolaes G.A., Dahlback B. Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol. 22:2002;530-538
27. Bick R.L. Prothrombin G20210A mutation, antithrombin, heparin cofactor II, protein C, and protein S defects. Hematol Oncol Clin N Am. 17:2003;9-36
28. Middeldorp S., Meinardi J.R., Koopman M.M., et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med. 135:2001;322-327
29. Martinelli I., Bucciarelli P., Margaglione M., De Stefano V., Castaman G., Mannucci P.M. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol. 111:2000;1223-1229
30. Nguyen A. Prothrombin G20210A polymorphism and thrombophilia. Mayo Clin Proc. 75:2000;595-604
31. Emmerich J., Rosendaal F.R., Cattaneo M., et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost. 86:2001;809-816
32. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Available at: www.acmg.net/resources/policies/pol-009.asp. Accessed November 17, 2003.
33. Rees D.C., Cox M., Clegg J.B. World distribution of factor V Leiden. Lancet. 346:1995;1133-1134
34. Ridker P.M., Miletich J.P., Hennekens C.H., Buring J.E. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA. 277:1997;1305-1307
35. Shen M.C., Lin J.S., Tsay W. Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan. Thromb Res. 99:2000;447-452
36. Rosendaal F.R., Doggen C.J., Zivelin A., et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 79:1998;706-708
37. Kodaira H., Ishida F., Shimodaira S., Takamiya O., Furihata K., Kitano K. Resistance to activated protein C and Arg 506 Gln factor V mutation are uncommon in eastern Asian populations. Acta Haematol. 98:1997;22-25
38. Hoppe C., Matsunaga A. Pediatric thrombosis. Pediatr Clin North Am. 49:2002;1257-1283
39. Chalmers E.A. Neonatal thrombosis. J Clin Pathol. 53:2000;419-423
40. Manco-Johnson M.J., Nuss R. Thrombophilia in the infant and child. Adv Pediatr. 48:2001;363-384
41. Nowak-Gottl U., Kosch A., Schlegel N. Thromboembolism in newborns, infants and children. Thromb Haemost. 86:2001;464-474
42. Nowak-Gottl U., Kosch A., Schlegel N., Salem M., Manco-Johnson M. Thromboembolism in children. Curr Opin Hematol. 9:2002;448-453
43. Sass A.E., Neufeld E.J. Risk factors for thromboembolism in teens: when should I test? Curr Opin Pediatr. 14:2002;370-378
44. Chalmers E.A. Heritable thrombophilia and childhood thrombosis. Blood Rev. 15:2001;181-189
45. Olds R.J., Lane D.A., Thein S.L. The molecular genetics of antithrombin deficiency. Br J Haematol. 87:1994;221-226
46. Jilma B., Kamath S., Lip G.Y. ABC of antithrombotic therapy: antithrombotic therapy in special circumstances II: in children, thrombophilia, and miscellaneous conditions. BMJ. 326:2003;93-96
47. Gibson C.S., MacLennan A.H., Goldwater P.N., Dekker G.A. Antenatal causes of cerebral palsy: associations between inherited thrombophilias, viral and bacterial infection, and inherited susceptibility to infection. Obstet Gynecol Surv. 58:2003;209-220
48. Mercuri E., Cowan F., Gupte G., et al. Prothrombotic disorders and abnormal neurodevelopmental outcome in infants with neonatal cerebral infarction. Pediatrics. 107:2001;1400-1404
49. Kearon C. Duration of therapy for acute venous thromboembolism. Clin Chest Med. 24:2003;63-72
50. Brandjes D.P., Buller H.R., Heijboer H., et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 349:1997;759-762
51. Martinelli I., Cattaneo M., Taioli E., De Stefano V., Chiusolo P., Mannucci P.M. Genetic risk factors for superficial vein thrombosis. Thromb Haemost. 82:1999;1215-1217
52. Bradbury A.W., MacKenzie R.K., Burns P., Fegan C. Thrombophilia and chronic venous ulceration. Eur J Vasc Endovasc Surg. 24:2002;97-104
53. Martinelli I., Sacchi E., Landi G., Taioli E., Duca F., Mannucci P.M. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 338:1998;1793-1797
54. Martinelli I. Unusual forms of venous thrombosis and thrombophilia. Pathophysiol Haemost Thromb. 32:2002;343-345
55. Bousser M.G. Cerebral venous thrombosis: diagnosis and management. J Neurol. 247:2000;252-258
56. Divino C.M., Park I.S., Angel L.P., Ellozy S., Spiegel R., Kim U. A retrospective study of diagnosis and management of mesenteric vein thrombosis. Am J Surg. 181:2001;20-23
57. Fegan C.D. Central retinal vein occlusion and thrombophilia. Eye. 16:2002;98-106
58. Gerhardt A., Scharf R.E., Beckmann M.W., et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med. 342:2000;374-380
59. Vandenbroucke J.P., Rosing J., Bloemenkamp K.W., et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 344:2001;1527-1535
60. Peverill R.E. Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab. 17:2003;149-164
61. Buchanan G.S., Rodgers G.M., Ware Branch D. The inherited thrombophilias: genetics, epidemiology, and laboratory evaluation. Best Pract Res Clin Obstet Gynaecol. 17:2003;397-411
62. Bloemenkamp K.W., Helmerhorst F.M., Rosendaal F.R., Vandenbroucke J.P. Thrombophilias and gynaecology. Best Pract Res Clin Obstet Gynaecol. 17:2003;509-528
63. Greer I.A. Inherited thrombophilia and venous thromboembolism. Best Pract Res Clin Obstet Gynaecol. 17:2003;413-425
64. Pabinger I., Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost. 71:1994;548-552
65. Greer I.A. Prevention and management of venous thromboembolism in pregnancy. Clin Chest Med. 24:2003;123-137
66. Brenner B., Kupferminc M.J. Inherited thrombophilia and poor pregnancy outcome. Best Pract Res Clin Obstet Gynaecol. 17:2003;427-439
67. Mammen E.F. Oral contraceptive pills and hormonal replacement therapy and thromboembolic disease. Hematol Oncol Clin N Am. 14:2000;1045-1059
68. Cerel-Suhl S.L., Yeager B.F. Update on oral contraceptive pills. Am Fam Physician. 60:1999;2073-2084
69. Kemmeren J.M., Algra A., Grobbee D.E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 323:2001;131-134
70. Vandenbroucke J.P., Koster T., Briet E., Reitsma P.H., Bertina R.M., Rosendaal F.R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 344:1994;1453-1457
71. Legnani C., Palareti G., Guazzaloca G., et al. Venous thromboembolism in young women: role of thrombophilic mutations and oral contraceptive use. Eur Heart J. 23:2002;984-990
72. Schambeck C.M., Schwender S., Haubitz I., Geisen U.E., Grossmann R.E., Keller F. Selective screening for the factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives? Thromb Haemost. 78:1997;1480-1483
73. Caplin N., Edelman L. Thrombophilia [letter and author reply]. N Engl J Med. 345:2001;697-699
74. Creinin M.D., Lisman R., Strickler R.C. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril. 72:1999;646-651
75. Vandenbroucke J.P., van der Meer F.J., Helmerhorst F.M., Rosendaal F.R. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ. 313:1996;1127-1130
76. Miller J., Chan B.K., Nelson H.D. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US Preventive Services Task Force. Ann Intern Med. 136:2002;680-690
77. Manson J.E., Martin K.A. Clinical practice: postmenopausal hormone-replacement therapy. N Engl J Med. 345:2001;34-40
78. Hays J., Ockene J.K., Brunner R.L., et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 348:2003;1839-1854
79. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 289:2003;3243-3253
80. Shumaker S.A., Legault C., Rapp S.R., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 289:2003;2651-2662
81. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 349:2003;523-534
82. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333
83. Andres R.L., Miles A. Venous thromboembolism and pregnancy. Obstet Gynecol Clin N Am. 28:2001;613-630
84. McCowan L.M., Craigie S., Taylor R.S., Ward C., McLintock C., North R.A. Inherited thrombophilias are not increased in "idiopathic" small-for-gestational-age pregnancies. Am J Obstet Gynecol. 188:2003;981-985
85. Infante-Rivard C., Rivard G.E., Yotov W.V., et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med. 347:2002;19-25
86. Said J., Dekker G. Pre-eclampsia and thrombophilia. Best Pract Res Clin Obstet Gynaecol. 17:2003;441-458
87. Kupferminc M.J., Fait G., Many A., Gordon D., Eldor A., Lessing J.B. Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol. 96:2000;45-49
88. Morrison E.R., Miedzybrodzka Z.H., Campbell D.M., et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost. 87:2002;779-785
89. Schlembach D., Beinder E., Zingsem J., Wunsiedler U., Beckmann M.W., Fischer T. Association of maternal and/or fetal factor V Leiden and G20210A prothrombin mutation with HELLP syndrome and intrauterine growth restriction. Clin Sci (Lond). 105:2003;279-285
90. Many A., Elad R., Yaron Y., Eldor A., Lessing J.B., Kupferminc M.J. Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia. Obstet Gynecol. 99:(5 Pt 1):2002;684-687
91. Rey E., Kahn S.R., David M., Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 361:2003;901-908
92. Subar M. Clinical evaluation of hypercoagulable states. Clin Geriatr Med. 17:2001;57-70
93. Ridker P.M., Glynn R.J., Miletich J.P., Goldhaber S.Z., Stampfer M.J., Hennekens C.H. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med. 126:1997;528-531
94. Hainaut P., Jaumotte C., Verhelst D., et al. Hyperhomocysteinemia and venous thromboembolism: a risk factor more prevalent in the elderly and in idiopathic cases. Thromb Res. 106:2002;121-125
95. Oger E., Lacut K., Van Dreden P., et al. High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderly. Haematologica. 88:2003;465-469
96. Nicolaes G.A., Dahlback B. Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states. Hematol Oncol Clin N Am. 17:2003;37-61
97. Svensson P.J., Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 330:1994;517-522
98. Koster T., Rosendaal F.R., de Ronde H., Briet E., Vandenbroucke J.P., Bertina R.M. Venous thrombosis due to poor anticoagulant response to activated protein C. Leiden Thrombophilia Study. Lancet. 342:1993;1503-1506
99. Papa A., Danese S., Grillo A., Gasbarrini G., Gasbarrini A. Review article: inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol. 98:2003;1247-1251
100. Wuthrich R.P. Factor V Leiden mutation: potential thrombogenic role in renal vein, dialysis graft and transplant vascular thrombosis. Curr Opin Nephrol Hypertens. 10:2001;409-414
101. Pherwani A.D., Winter P.C., McNamee P.T., et al. Is screening for factor V Leiden and prothrombin G20210A mutations in renal transplantation worthwhile? Results of a large single-center UK study. Transplantation. 76:2003;603-605
102. Folsom A.R., Cushman M., Tsai M.Y., et al. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood. 99:2002;2720-2725
103. Rosendaal F.R., Koster T., Vandenbroucke J.P., Reitsma P.H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 85:1995;1504-1508
104. Middeldorp S., Henkens C.M., Koopman M.M., et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med. 128:1998;15-20
105. Martinelli I., Cattaneo M., Panzeri D., Mannucci P.M. Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost. 77:1997;440-443
106. Manten B., Westendorp R.G., Koster T., Reitsma P.H., Rosendaal F.R. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost. 76:1996;510-513
107. Baglin T.P., Brown K., Williamson D., Baker P., Luddington R. Relative risk of pulmonary embolism and deep vein thrombosis in association with the factor V Leiden mutation in a United Kingdom population. Thromb Haemost. 77:1997;1219
108. De Stefano V., Martinelli I., Mannucci P.M., et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 341:1999;801-806
109. Eichinger S., Pabinger I., Stumpflen A., et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost. 77:1997;624-628
110. Baglin T., Luddington R., Brown K., Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 362:2003;523-526
111. Martinelli I., De Stefano V., Taioli E., Paciaroni K., Rossi E., Mannucci P.M. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost. 87:2002;791-795
112. Bloomenthal D., von Dadelszen P., Liston R., Magee L., Tsang P. The effect of factor V Leiden carriage on maternal and fetal health. Can Med Assoc J. 167:2002;48-54
113. Reuner K.H., Ruf A., Grau A., et al. Prothrombin gene G20210→A transition is a risk factor for cerebral venous thrombosis. Stroke. 29:1998;1765-1769
114. De Stefano V., Martinelli I., Mannucci P.M., et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol. 113:2001;630-635
115. Protein C deficiency (website). Available at: www.ncbi.nlm.nih.gov/Omim/ searchomim.html. Accessed November 17, 2003.
116. Kottke-Marchant K., Comp P. Laboratory issues in diagnosing abnormalities of protein C, thrombomodulin, and endothelial cell protein C receptor. Arch Pathol Lab Med. 126:2002;1337-1348
117. Reich L.M., Bower M., Key N.S. Role of the geneticist in testing and counseling for inherited thrombophilia. Genet Med. 5:2003;133-143
118. Chan Y.C., Valenti D., Mansfield A.O., Stansby G. Warfarin induced skin necrosis. Br J Surg. 87:2000;266-272
119. Goodwin A.J., Rosendaal F.R., Kottke-Marchant K., Bovill E.G. A review of the technical, diagnostic, and epidemiologic considerations for protein S assays. Arch Pathol Lab Med. 126:2002;1349-1366
120. Zoller B., Berntsdotter A., Garcia de Frutos P., Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 85:1995;3518-3523
121. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 13:1965;516-530
122. Antithrombin III deficiency (website). Available at: www.ncbi.nlm.nih. gov/Omim/searchomim.html. Accessed November 17, 2003.
123. van Boven H.H., Vandenbroucke J.P., Briet E., Rosendaal F.R. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency. Blood. 94:1999;2590-2594
124. den Heijer M., Keijzer M.B. Hyperhomocysteinemia as a risk factor for venous thrombosis. Clin Chem Lab Med. 39:2001;710-713
125. Briet E., van der Meer F.J., Rosendaal F.R., Houwing-Duistermaat J.J., van Houwelingen H.C. The family history and inherited thrombophilia. Br J Haematol. 87:1994;348-352
126. Cosmi B., Legnani C., Bernardi F., Coccheri S., Palareti G. Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception. Arch Intern Med. 163:2003;1105-1109
127. Mannucci P.M. Genetic hypercoagulability: prevention suggests testing family members. Blood. 98:2001;21-22
128. ACOG Practice Bulletin: Thromboembolism in pregnancy. Number 19, August 2000. Compendium of Selected Publications. 2003;The American College of Obstetricians and Gynecologists, Washington, DC. 633-42
129. Federman D.G., Kirsner R.S. An update on hypercoagulable disorders. Arch Intern Med. 161:2001;1051-1056
130. Clark P., Twaddle S., Walker I.D., Scott L., Greer I.A. Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women. Lancet. 359:2002;1919-1920
131. Rouse D.J., Goldenberg R.L., Wenstrom K.D. Antenatal screening for factor V Leiden mutation: a critical appraisal. Obstet Gynecol. 90:1997;848-851
132. Wheeler H.B. Should surgical patients be screened for thrombophilia? Semin Thromb Hemost. 24:(Suppl 1):1998;63-65
133. Bauer K.A. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med. 135:2001;367-373
134. Bowles L., Cohen H. Inherited thrombophilias and anticoagulation in pregnancy. Best Pract Res Clin Obstet Gynaecol. 17:2003;471-489
135. Ginsberg J.S., Greer I., Hirsh J. Use of antithrombotic agents during pregnancy. Chest. 119:(1 Suppl):2001;122S-131S